FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs

Details for Australian Patent Application No. 2007315213 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

Inventors Roidl, Andreas; Berger, Hans-Jurgen; Ullrich, Axel

Agent Davies Collison Cave

Pub. Number AU-A-2007315213

PCT Pub. Number WO2008/052798

Priority 06022946.5 03.11.06 EP

Filing date 2 November 2007

Wipo publication date 8 May 2008

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

4 June 2009 PCT application entered the National Phase

  PCT publication WO2008/052798 Priority application(s): WO2008/052798

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007315217-Modular laboratory apparatus for analysis and synthesis of liquids and method for analysis and synthesis of liquids

2007315211-FGFR4 antibodies